Three patients with hematologic relapse after bone marrow transplantation for chronic myelogenous leukemia were treated with interferon a and transfusion of viable donor buffy coat. All had complete hematologic and cytogenetic remission, which persisted 32 to 91 weeks after treatment. In two patients graft-versus-host disease devel-
oped and was treated by immunosuppression. These results are an example of adoptive immunotherapy without cytoreductive chemotherapy or radiotherapy in human chimeras. 0 1990 by The American Society of Hematology.
polymorphism. DNA was extracted, digested with HinfI (Fa. Biozym, Hameln, Germany), and separated in agarose gel electrophoresis (0.8%) by routine methods." It was transferred to a nylon membrane (Geen Screen Plus, Fa. Dupont, Dreieich, Germany) as described by Southern" and hybridized with the minisatellite probes under highly stringent conditions. The sensitivity of this method is 5% according to mixing experiments.
Cytogenetic preparations were obtained from 2-hour cultures without stimulation. G-banding was performed according to the method of SeabrightI2 with some modifications. Analyses were done on at least 20 metaphases, whenever possible. Markers of chimerism are summarized in Table 1 .
IFNa 2b (Intron A, Fa. Essex Pharma, Miinchen, Germany) was administered daily in a dose of 5 x lo6 U/m2 subcutaneously. The dose was decreased in cases of cytopenia.
Buffy coat was prepared from the marrow donor by a continuous flow cell separator (Fa. Cobe, Denver, CO, model 5000). Between 250 mL and 365 mL were collected per session, and between three and five sessions were performed within 5 to 9 days.
RESULTS
Patient unique patient number (UPN) 105, a 22-year-old man, was transplanted in chronic phase on April 4, 1985 with marrow from his HLA-identical brother with 4.2 x 10S/kg nucleated cells. The patient had blood group A and his donor B. He did not develop clinically significant GVHD. CML recurred 3 years later in chronic phase. The degree of chimerism decreased as shown by PGM 1, al,2 positive cells and the reappearance of RBCs of blood group A ( Table 2) . He was treated with IFNa from June through September 1988 with a decrease of leukocyte counts from 60 g/L and 13.8 g/L. The lactate dehydrogenase (LDH) remained elevated and the karyotype of all marrow cells had the Philadelphia (Phl) chromosome. In addition, a new clone characterized by a 14q+ chromosome evolved and expanded. He received four viable buffy coat transfusions containing 4.4 x 108/kg nucleated cells from his marrow donor. IFNa was discontinued. Seven weeks later, 6 of 18 marrow cells were Phl-negative. At the same time he presented with a generalized skin rash and increased liver enzymes. Immunosuppressive therapy with CSA, prednisolone, and azathioprin was started 10 weeks later because of rising bilirubin (peak value: 8.3 mg/dL) and deteriorating skin changes. GVHD responded promptly and immunosuppressive medication was decreased and discontinued. Nine weeks after buffy coat transfusion all marrow cells were Phl-negative. Repeated examinations at 15,24,46, 52,60, and 91 weeks showed only Phl-negative cells in his marrow (Table 3) . Chimerism is again complete as tested by typing of blood groups, isoenzymes, and RFLP.
Patient UPN 139, a 39-year-old woman, was transplanted on April 16, 1986 with 3.7 x 108/kg nucleated marrow cells from her HLA-identical brother. She did not develop clinically significant GVHD. In June 1989 she had a recurrence of CML in chronic phase with immature cells in the blood and 78% Phl-positive, female cells in the marrow. She was treated with IFNa starting August 1989 without improvement. The differential count was unchanged and she developed bone pain. In October 1989 she received four transfusions of viable buffy coat from her marrow donor containing 7.4 x 108/kg nucleated cells. A month later the patient developed itching and a generalized rash. IFNa was discontinued. Six weeks after the transfusion she presented with GVHD grade I1 and encephalitis characterized by a opsomyoclonic syndrome. A spinal tap showed a slight increase of cells and protein, computed tomography scan and nuclear magnetic resonance tomography (MR) scan were unremarkable. She was started on immunosuppressive treatment with prednisolone, CSA, and azathioprin and recovered slowly. Sixteen and 32 weeks after transfusion her marrow cells were all male and Phl-negative (Table 3) 
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46 XY P h l + (18) 46 XY P h l + 14q+ (1) 46XY Phl + 14q+ (15) 46 XY Phl + (12) 46 XY Phl - (6) 46 XY P h l - For personal use only. on June 9, 2017. by guest www.bloodjournal.org From remissions.' Cytogenetic examinations in two of our patients after 11 and 14 weeks of IFN therapy showed persistent Phi-chromosome. A new clone evolved in one. In contrast, complete cytogenetic responses were seen 9 and more weeks after buffy coat transfusions. Although none of these patients developed GVHD after transplantation, two developed clinically significant GVHD after donor buffy coat transfusion.
In canine chimeras transfusion of donor buffy coat did not induce GVHD unless donors were sensitized,14 suggesting active mechanisms of GVH tolerance. Donors of our patients were males who had not been transfused previously. Mechanisms of tolerance may differ with GVHD prophylaxis, ie, CSA instead of methotrexate, and tolerance may be disturbed by treatment with IFNa. Alternatively, the reappearance of host-type hematopoietic cells, particularly monocytes with the leukemic clone may be a precondition for the development of acute GVHD after buffy coat transfusions. The role of host-type monocytes and tumor necrosis factor a has been previously discus~ed.'~ In both patients GVHD resolved under immunosuppressive treatment.
Neurologic complications as in our patient UPN 139 have recently been described by others in patients with CML treated with I F N a for recurrence after transplantation. 16 In our patient symptoms disappeared after immunosuppressive treatment.
GVHD is associated with an antileukemic effect," and patients with chronic GVHD may have improved survival.18 This antileukemic effect of GVHD is well documented in both acute leukemia and CML.".I9 Depletion of T cells from the marrow graft decreases the incidence of GVHD and increases the risk of recurrent le~kemia.~,",~' However, depletion of T cells also increases the risk of recurrent leukemia in patients who develop GVHD." Therefore, neither does the presence of GVHD guarantee a strong antileukemic effect, nor does the absence of GVHD indicate the absence of an antileukemic effect. In our patient UPN 169 the malignant clone disappeared without development of GVHD.
The treatment of our patients is an example of successful adoptive immunotherapy. Several aspects differ from a prior study of adoptive immunotherapy reported by Sullivan et aL2' Their patients had acute leukemia and were transfused with buffy coat early after transplant. In our patients, chimerism was already established for a long period of time before buffy coat transfusion. In addition, our patients did not receive prophylactic immunosuppressive therapy, but they did receive IFN. IFN may have supported cytotoxic activity of the transfused cells. IFN has differential effects on the expression of class I and class I1 antigens.22 Increased expression of class I HLA antigens as restricting elements of minor histocompatibility antigens (HA) may support cellmediated cytotoxicity of transfused buffy coat cells against host-type hematopoietic cells. Minor H A are differentially expressed on hematopoietic progenitor cells23 and the cytotoxic reaction against minor H A is restricted by class I HLA antigens.24 A GVH reaction against minor H A of the host appears more likely than a reaction against potential leukemia-specific antigens. With the disappearance of Phlpositive metaphases all hematopoietic cells of host type disappeared. We don't know whether all hematopoietic cells of host type were produced by the Phl-positive clone or whether some were produced by residual normal host hematopoiesis. However, specificity for minor H A on hematopoietic cells of the host may be sufficient for an antileukemic effect without the risk of severe clinical GVHD.
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